Ye Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Ye Zhang has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Aoran Liu
The Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, China
1 shared publicationDan Zou
Department of Oncology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, China
1 shared publicationFang Li
The Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, China
1 shared publicationJipeng Mei
The Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, China
1 shared publication- Lina Wu
Department of Laboratory Medicine, Shengjing Hospital of China Medical University, No. 36, San Hao Street, Shenyang, China
1 shared publication Lirong Yan
The Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, China
1 shared publication
Latest Publications
- Open Access
- 10 December 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1)
De-ubiquitinase USP35 promotes peritoneal dissemination of gastric cancer by regulating metabolic reprogramming
The enhanced adhesion between gastric cancer (GC) cells and peritoneal mesothelial cells (PMCs) is one of the key factors in the formation of the pre-peritoneal-metastasis adaptive microenvironment. USP35 belongs to the ubiquitin-specific protease family and is involved in regulating the occurrence and progression of various diseases. However, whether this gene can regulate the adhesion of GC cells to PMCs has not been clarified. The aim of this study was to identify the mechanism by which USP35 promotes the formation of the pre-peritoneal-metastasis adaptive microenvironment of GC and to find potential therapeutic targets. For the first time, we found that USP35 expression is upregulated in GC tissues, especially in peritoneal metastatic nodules, and is associated with poor prognosis. USP35 expression is the highest in MKN-45P, which is closely related to its high peritoneal metastasis potential. The mechanism of action involves several key steps. Firstly, the gene targets STING through de-ubiquitination and stabilizes its expression. Through this interaction, USP35/STING activates the HIF-1α/FAK pathway, promoting energy metabolism reprogramming and further improving the adhesion ability of GC cells. Secondly, exosome USP35 derived from GC cells has been shown to promote the mesothelial–mesenchymal transformation (MMT) of PMCs, preparing the “soil” for cancer cell adhesion and growth and contributing to the establishment of a pre-peritoneal-metastasis adaptive microenvironment. In summary, USP35 synergistically promotes the establishment of this environment through the dual mechanisms of regulating energy metabolic reprogramming of tumor cells and inducing the MMT of PMCs via the exosome pathway, providing a new theoretical basis for searching for therapeutic targets of gastric cancer with peritoneal dissemination.
- 10 December 2025
- Published by Springer Nature in Cell Death & Disease
- Vol. 16 (1)
Open AccessDe-ubiquitinase USP35 promotes peritoneal dissemination of gastric cancer by regulating metabolic reprogramming
The enhanced adhesion between gastric cancer (GC) cells and peritoneal mesothelial cells (PMCs) is one of the key factors in the formation of the pre-peritoneal-metastasis adaptive microenvironment. USP35 belongs to the ubiquitin-specific protease family and is involved in regulating the occurrence and progression of various diseases. However, whether this gene can regulate the adhesion of GC cells to PMCs has not been clarified. The aim of this study was to identify the mechanism by which USP35 promotes the formation of the pre-peritoneal-metastasis adaptive microenvironment of GC and to find potential therapeutic targets. For the first time, we found that USP35 expression is upregulated in GC tissues, especially in peritoneal metastatic nodules, and is associated with poor prognosis. USP35 expression is the highest in MKN-45P, which is closely related to its high peritoneal metastasis potential. The mechanism of action involves several key steps. Firstly, the gene targets STING through de-ubiquitination and stabilizes its expression. Through this interaction, USP35/STING activates the HIF-1α/FAK pathway, promoting energy metabolism reprogramming and further improving the adhesion ability of GC cells. Secondly, exosome USP35 derived from GC cells has been shown to promote the mesothelial–mesenchymal transformation (MMT) of PMCs, preparing the “soil” for cancer cell adhesion and growth and contributing to the establishment of a pre-peritoneal-metastasis adaptive microenvironment. In summary, USP35 synergistically promotes the establishment of this environment through the dual mechanisms of regulating energy metabolic reprogramming of tumor cells and inducing the MMT of PMCs via the exosome pathway, providing a new theoretical basis for searching for therapeutic targets of gastric cancer with peritoneal dissemination.